Trastuzumab deruxtecan achieves tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial

Image: Trastuzumab deruxtecan has achieved tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial. Photo: courtesy of AstraZeneca.